News
Stay up to date
Follow the latest on our journey, as we are living innovation!
Lakefront Biotherapeutics is dedicated to building a differentiated pipeline of medicines for patients with serious diseases.
Lakefront has established a clinical-stage portfolio in immunology and inflammation, anchored by lead asset gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases.
Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value.
We combine disciplined business development with focused execution and apply a high bar to portfolio expansion.
Pipeline
We focus on delivering best-in-class medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need.
Meet the members of our Executive Committee and our Management Team. They are driving innovation to deliver life-changing treatments for patients worldwide, together.
News
Follow the latest on our journey, as we are living innovation!
Investors
Looking for the latest presentations, upcoming events, and financial highlights?